Julie Kay Cahill

This inventor holds 6 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Kudos Pharmaceuticals Limited, Astrazeneca Ab. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julie Kay Cahill. Retrieved from https://idiyas.com/inventor/julie-kay-cahill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 18(Granted Patents)

Company Filing History:

5 out of 36

Kudos Pharmaceuticals Limited

Years Active: 2013-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12178816 - Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one (2024-12-31),

2. 12144810 - Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one (2024-11-19),

3. 12048695 - Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one (2024-07-30),

4. 11975001 - Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one (2024-05-07),

5. 11633396 - Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one (2023-04-25),

6. 8475842 - Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one (2013-07-02),

Title: Julie Kay Cahill: Innovator in Pharmaceutical Formulations

Introduction

Julie Kay Cahill is a distinguished inventor based in Macclesfield, GB. She has made significant contributions to the field of pharmaceuticals, holding a total of six patents. Her work focuses on innovative formulations that enhance drug bioavailability and efficacy.

Latest Patents

One of her latest patents is an immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one. This invention relates to a pharmaceutical formulation that includes the drug in a solid dispersion with a matrix polymer exhibiting low hygroscopicity and high softening temperature, such as copovidone. The formulation aims to provide a daily pharmaceutical dose of the drug while increasing its bioavailability.

Career Highlights

Throughout her career, Julie has worked with notable companies such as Kudos Pharmaceuticals Limited and AstraZeneca. Her experience in these organizations has allowed her to develop and refine her innovative approaches to pharmaceutical formulations.

Collaborations

Julie has collaborated with esteemed colleagues, including Kieran James Lennon and Michael Karl Bechtold. These partnerships have contributed to her success in the pharmaceutical industry.

Conclusion

Julie Kay Cahill is a prominent figure in the realm of pharmaceutical innovations, with a focus on enhancing drug formulations. Her contributions continue to impact the industry positively.

Profile summary based on public USPTO records.